AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00552526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiepileptic drug (AED)
Description: An AED,not used by the patient before, which we consider to be the most appropriate will be given orally or by gastrostomy. Serum concentration, the body weight, side effects and effects on the epilepsy will be considered when deciding the dose of the AED. Traditions for amount of medicine/kg body weight or optimal serum concentration at our center will be followed. This tradition will be the same as in other major European epilepsy centers but might propose lower, but not higher amounts than recommended by the drug company. Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate, zonisamide, vigabatrin, tiagabil, lamotrigine, pregabalin, rufinamide, clobazam, clonazepam, tiagabine, gabapentin, phenytoin, phenobarbital, ethosuximide, acetazolamide, nitrazepam and other new antiepileptic drugs that might be released during the study period.
Study NCT01480271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 ng GSK2445053
Description: 2ng GSK2445053 administered intranasally
Study NCT01480271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20ng GSK2445053
Description: 20ng GSK2445053 administered intranasally
Study NCT01480271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100ng GSK2445053
Description: 100ng GSK2445053 administered intranasally
Study NCT01480271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200ng GSK2445053
Description: 200ng GSK2445053 administered intranasally
Study NCT01480271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400ng GSK2445053
Description: 400ng GSK2445053 administered intranasally
Study NCT01480271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000ng GSK2445053
Description: 1000ng GSK2445053 administered intranasally
Study NCT01480271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2000ng GSK2445053
Description: 2000ng GSK2445053 administered intranasally
Study NCT01480271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4000ng GSK2445053
Description: 4000ng GSK2445053 administered intranasally
Study NCT01480271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intranasally
Study NCT03877237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
Study NCT03877237 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
Study NCT02086526 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Approximately 37 patients will start metformin therapy 3 months after their visit 2. All other patients will receive metformin therapy at their visit 2.
Study NCT02086526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Approximately 37 patients will start metformin therapy 3 months after their visit 2. All other patients will receive metformin therapy at their visit 2.
Study NCT00916422 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergen extract (Phleum pratense)
Description: Subcutaneous immunotherapy with modified extract of Phleum pratense. A subcutaneous monthly treatment.
Study NCT00916422 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous monthly treatment
Study NCT04575038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brequinar
Description: Dihydroorotate dehydrogenase inhibitor (DHODHi)
Study NCT04575038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT02703883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BWST
Description: BWST (six weeks, 3 times/week)
Study NCT03786601 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: The participants were assigned to different groups according to the results of HPV detection.
Study NCT02204683 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept
Description: Intravitreal aflibercept
Study NCT03517774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Printed Socket
Description: Twenty participants will be fitted with a 3D Printed socket created using 3DPrintAbility hardware and software. To do this, a 3D model of the participants residual limb will be generated which will be used to create the 3D printed sockets. These 20 participants will also receive standard care for prosthetic fitting at SJR. The fittings will be done by one prosthetist. Our team will compare the feasibility, function, quality and stability of the prosthetics through quantitative, economic and qualitative analyses. All fittings will be done under the supervision of a qualified Sunnybrook prosthetist who has previous experience with using 3D printed technologies for creation of prosthetics.
Study NCT02856451 — intervention group
Intervention type: BIOLOGICAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT00384358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBMP-2/CPM
Description: one time injection of 3-5 mL test article at time of internal fracture fixation
Study NCT00384358 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: surgical intervention alone
Description: surgical internal fixation of fracture defines the standard of care group
Study NCT00667719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 300 mg tablet
Study NCT00667719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5 mg tablet
Study NCT00667719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: 12.5 mg and 25 mg capsule
Study NCT03618082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesic agent guided by ANI (Interventional Group)
Description: Anesthesic agent guided by ANI (Interventional Group) The remifentanil administration will be piloted by the ANI, as well as the prophylactic administration of morphine at the end of the intervention.
Study NCT03618082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesic agent guided by ANI (Interventional Group)
Description: Anesthesic agent guided by ANI (Interventional Group) The remifentanil administration will be piloted by the ANI, as well as the prophylactic administration of morphine at the end of the intervention.
Study NCT03618082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of the lowest effective concentration of desflurane (Interventional Group)
Description: Administration of the lowest effective concentration of desflurane (Interventional Group) Desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC).
Study NCT03618082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of the lowest effective concentration of desflurane (Interventional Group)
Description: Administration of the lowest effective concentration of desflurane (Interventional Group) Desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC).
Study NCT01684449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Rapamycin
Description: Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).~Every three weeks until disease progression or unacceptable toxicity. The treatment will last for 6 cycles if there is not progression or intolerable toxicity.~Additionally, there will be a pharmacokinetic study in a minimum of 9 patients treated with the drug combination.
Study NCT02360410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Yourself App with Feedback
Study NCT03582501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure
Description: Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
Study NCT03893409 — intervention group
Intervention type: OTHER
Description: this is a observation study, no any intervention in patients
Study NCT02778568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training exercises
Study NCT02778568 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Stretching exercises
Study NCT04191174 — intervention group
Intervention type: OTHER
Intervention: Hyperpolarized 129Xe MRI
Description: Hyperpolarized 129Xe MRI to evaluate ventilation heterogeneity
Study NCT04191174 — intervention group
Intervention type: OTHER
Intervention: Technegas V SPECT
Description: Technegas V SPECT to evaluate ventilation heterogeneity
Study NCT04191174 — intervention group
Intervention type: OTHER
Intervention: Sputum Induction
Description: Sputum induction to evaluate luminal cellular inflammation
Study NCT02149550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NF135 n=5
Description: Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
Study NCT01156181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical discharge removal
Description: Cervical discharge will be removed using a cotton swab before embryo transfer during ICSI cycles
Study NCT04040127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord blood stem cells
Description: Umbilical cords are collected from eligible donors at the time of delivery and transported to the processing facility on ice (2-8℃) in Dulbecco's Modified Eagle Media (DMEM). Cords are processed immediately under aseptic conditions and MSCs are collected for culture. Culture is maintained this way until the target number of cells has been reached, at which point passaged cells are suspended in Stem Cellbanker (Amsbio, Cambridge, MA) and frozen at -80℃.
Study NCT04040127 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: saline solution used to rinse the canal.
Study NCT01248884 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: 3 doses, intramuscular into left thigh
Study NCT01248884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13®
Description: 3 co-administered doses, intramuscular into right thigh
Study NCT01248884 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13®
Description: 3 co-administered doses, intramuscular into right thigh
Study NCT01248884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK217744
Description: 3 doses, intramuscular into left thigh
Study NCT01100164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
Study NCT01100164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zopiclone
Description: Zopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
Study NCT03149094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBSM-SMI
Description: The intervention group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.
Study NCT03149094 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBSM-SMI control
Description: this group will receive the LifeSum app.
Study NCT01721018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV1716 Intra-pleural delivery
Study NCT00003011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marimastat
Description: 10 mg PO BID
Study NCT00003011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg PO BID
Study NCT02334800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 75 mg Capsule
Description: Single oral 75 mg dose of palbociclib followed by serial PK sampling up to 192 hours post-dose (up to 120 hours post-dose for the healthy volunteer cohort).
Study NCT02853968 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw/buccal swab
Description: The research project will need a blood sample of no more than 50mL per two month period. The research project may also request a buccal swab from patients if needed.
Study NCT02828111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patidegib
Study NCT02828111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Study NCT01428960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palm Mid Fraction, Shea Butter, High Oleic Sunflower Oil
Description: Acute effect of sn-1 and sn-3 palmitic acid-rich or stearic acid-rich fats on postprandial lipemia, haemostatic and inflammatory markers, gut hormone concentrations, satiety, and insulinemic response in human volunteers ; 6 wk each with 2 week wash out in between
Study NCT03721991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gama amino butyric acid (GABA)
Description: food supplement Gama amino butyric acid (GABA) as capsules
Study NCT03721991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study NCT03579563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AUD fitting
Description: Prescription hearing aids will be fitted by audiologists using established procedures.
Study NCT03579563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTC+ fitting
Description: Audiology professionals provide brief services to fit preset-based OTC hearing aids, which are simulated using prescription hearing aids.
Study NCT03579563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTC fitting
Description: In this group, preset-based OTC hearing aids, which are simulated using prescription hearing aids, will be provided to subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
Study NCT03579563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-end HA
Description: High-end hearing aids will be used.
Study NCT03579563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-end HA
Description: High-end hearing aids will be used.
Study NCT03579563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-end HA
Description: Low-end hearing aids will be used.
Study NCT03579563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-end HA
Description: Low-end hearing aids will be used.
Study NCT02149550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NF135 n=2
Description: Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
Study NCT02149550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NF135 n=1
Description: Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
Study NCT02149550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NF166 n=5
Description: Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
Study NCT02149550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NF166 n=2
Description: Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
Study NCT02149550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NF166 n=1
Description: Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
Study NCT04583839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation Program
Description: SWEET is a GDM-focused intervention that will apply barrier-reduction patient navigation strategies to improve health after a pregnancy with GDM. Women in SWEET will receive GDM-specific, tapered, individualized navigation services, including logistical support, psychosocial support, and patient education, through 1-year postpartum.
Study NCT01407575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)
Study NCT01407575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study NCT03746301 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban(Xarelto,BAY 59-7939)
Description: 10mg, 15mg and 20 mg film-coated tablets
Study NCT00764803 — intervention group
Intervention type: DEVICE
Intervention: Encore 3DKnee™ system
Description: Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore 3DKnee™ system and willing to participate in the study.
Study NCT00764803 — intervention group
Intervention type: DEVICE
Intervention: Encore MJS™ Knee System
Description: Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore MJS™ Knee system and willing to participate in the study.
Study NCT03124797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD DCI Sensor
Description: Noninvasive pulse oximeter sensor
Study NCT03779594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Patients will be assign and treated by acetazolamide from time of allocation until surgery (2-6 weeks after treatment initiation). The maximal dose of acetazolamide will be the same dose used to treat glaucoma, considering similarity of patients' characteristics, such as age and polypharmacy. We will start at a low dose of 250 mg once a day, and increase it slowly to a maximal dose of 500 mg twice a day. Dose will be individualized according to side-effects and tolerability. Renal and liver function tests will be performed before initiation of treatment, and will be examined again two weeks after treatment had begun.
Study NCT02156349 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Accu-Chek Smart Pix Software
Description: Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
Study NCT02156349 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Accu-Chek Smart Pix readout Device
Description: Smartpix device for data upload out of blood glucose meter devices
Study NCT03812679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMIA APD Solution Generation System
Description: The AMIA APD Solution Generation System consists of the AMIA APD Cycler, Sharesource Platform, AMIA APD Concentrates, a disposable set, a bag tray, a Water Softener, and a Water Device (WD).
Study NCT01917578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: 1. Evaluation of the tumor size by sonography is performed before neoadjuvant chemotherapy and prior to surgery.~2. Measurement of tumor size refers to WHO standards.
Study NCT01917578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CNB
Description: Typically, the pretreatment tumor specimen will be a core needle biopsy. Because 15% to 28% of patients will have no residual tumor after NAT, it is important to have an adequate pretreatment sample in which an unequivocal diagnosis of invasive carcinoma is established and evaluation of hormone receptors and HER2/ neu status is completed before treatment.
Study NCT01917578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BCS, Modified Radical Mastectomy
Description: All patients after neoadjuvant chemotherapy are performed BCS and modified radical mastectomy.
Study NCT01917578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pathologic Large Tissue Selected Table
Description: 1. Pathologic large tissue selected table has obtained Chinese patent.Its license ID is CN101261200.~2. Each piece of breast tissues by cutting with the table has 3mm thickness.
Study NCT01917578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leica TP1020
Description: Procedure:~1. Alcohol 70 % 1h~2. Alcohol 80 % 1h~3. Alcohol 85 % 1h~4. Alcohol 90 % 1h~5. Alcohol 95 % 1h~6. Alcohol Ⅰ 100 % 1h~7. Alcohol Ⅱ 100 % 1h~8. Xylene Ⅰ 2h~9. Xylene Ⅱ 2h~10. Xylene Ⅲ 2h~11. Paraffin 6h~12. Paraffin 6h
Study NCT01917578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pathologic Large Tissue Embedded Table
Description: 1. The table is made of brass .It is applying for a chinese patent.~2. The table can simultaneously embed 8 piece of breast tissues.
Study NCT01917578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leica SM2000 R
Description: Each of paraffin section has 4 um thickness.